ILs are expressed in median and range; upper and lower limits of IFN-γ increased significantly (p = 0.001) in MS patients treated with GA or IFN-β by 60 range (0–160), compared with the control group 0 (0–106) (Figure 3A). The gene discussed is IFNB1; the disease is myeloid sarcoma.